# Supplemental data

|  |  |  |  |
| --- | --- | --- | --- |
| Model | NEDA-3 Violation | Relapse | New Lesion |
| **Model 1 (Interaction Model)**Abnormal sNfL + Thin GCIP + Abnormal sNfL \* Thin GCIP | Abnormal sNfL (HR [95% CI]) |
| 0.98 [0.35-2.70], p = 0.97 | 2.37 [0.53-10.58], p = 0.26 | 0.87 [0.28-2.68], p = 0.81 |
| Thin GCIP (HR [95% CI]) |
| 0.90 [0.41-2.01], p = 0.80 | 2.98 [0.90-9.90], p = 0.08 | 0.60 [0.23-1.57], p = 0.30 |
| Abnormal sNfL \* Thin GCIP (HR [95% CI]) |
| **4.07 [1.12-14.81], p = 0.03** | 0.76 [0.13-4.58], p = 0.77 | **6.13 [1.40-26.81], p = 0.02** |
| AP [95% CI] |
| **0.75 [0.41-1.10], p = 1.79e-5** | 0.19 [-0.67-1.06], p = 0.66 | **0.85 [0.49-1.21], p = 3.70e-6** |
| **Model 2 (Additive Model)**Abnormal sNfL + Thin GCIP | Abnormal sNfL (HR [95% CI]) |
| **2.24 [1.25-4.02], p = 0.007** | 1.96 [0.86-4.48], p = 0.11 | **2.41 [1.27-4.59], p = 0.007** |
| Thin GCIP (HR [95% CI]) |
| 1.63 [0.91-2.92], p = 0.10 | **2.65 [1.08-6.50], p = 0.03** | 1.38 [0.72-2.62], p = 0.33 |
| Model Comparison(log likelihood ratio difference) | Model 1 v.s. Model 2 (reference) |
| **4.93 (p = 0.03)** | 0.09 (p = 0.77) | **6.57 (p = 0.01)** |

**Table e-6:** Model comparison and interaction analysis of abnormal sNfL and thin GCIP for future disease activity outcomes

Abbreviations: NEDA-3: no evidence of disease activity-3 criteria; AP: attributable proportion; GCIP: ganglion cell and inner plexiform layer.